Alloy Therapeutics and Echo Investment Capital have formed Wheeler Bio, a new biomanufacturing company built to accelerate the translation of therapeutic innovation into clinical impact. Wheeler’s discovery-to-IND programs are designed to provide emerging biopharma companies a faster and more predictable path to the clinic.   With an initial focus on antibody therapeutics, Wheeler’s biomanufacturing programs will integrate with Alloy Therapeutic’s preclinical antibody platforms and discovery cap...